Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Sarepta Therapeutics

Roche Holding AG  made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's  investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States –

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

Roche spent $12.3 billion in research & development (R&D) expenses in 2018. This figure is one of the highest among pharmaceutical companies.

How Big Is Roche’s R&D Expense?

Approval Of The Spark Deal Only Part Of An Expanding R&D-Driven Opportunity At Roche

Spark Therapeutics

Roche Holding (OTCQX: RHHBY) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc.

Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition

Swiss drugmaker Roche  plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics  on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.

Roche to complete $4.3 billion Spark deal as regulators give all clear

Swiss drugmaker Roche  has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics , the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A.

U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics

Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.

Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.

Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

Precision Biosciences

Forty Seven Inc

Mustang Bio

TG Therapeutics

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

5 Stocks Moving On ASH Presentations

ArQule

Merck

Sanofi

Synthorx Inc

Week Begins with Biotech Mergers

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.

Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC

Roche Could Leapfrog Biogen And Novartis In SMA Market

Bristol-Myers

GlaxoSmithKline

Pfizer

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

Roche Holding (NASDAQ: RHHBY) spent over $12 billion on R&D in 2018, making it the highest spender on R&D (in dollar terms) among large pharmaceutical companies globally. Roche has been investing heavily in R&D as it was looking for new drugs that could compensate the expected loss of revenue.

How Much Does Roche Spend On R&D: $5 Bil, $10 Bil, Or $20 Bil?

Analog Devices

Analog Devices, Inc. (ADI) CEO Vincent Roche on Q4 2019 Results - Earnings Call Transcript

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

Roche Holding (SWX: ROG) can add $5 billion in new oncology drugs revenue between 2018-2021. Roche will soon face biosimilar competition for its older oncology drugs ~ Avastin, Herceptin, and Rituxan.

Roche’s New Oncology Drugs To Add $5 Billion In Sales By 2021?

The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q3 2019 Results - Earnings Call Transcript

Roche Holding (SWX: ROG) has added roughly $6 billion in sales between 2015-2018. However, the company’s key blockbuster drugs – Avastin, Herceptin, and Rituxan – will likely be competing with biosimilars given the patent losses.

Despite Key Patent Losses Roche Could Add $5 Billion In Sales Over The Next 3 Years

Roche's acquisition of Spark will likely close before year's end, an analyst said after reports suggested U.S. regulators would bless the deal.

Why Roche's Acquisition Of Spark May Be Complete By Year's End

The Federal Trade Commission staff reviewing Roche's  plan to buy U.S.-based gene therapy specialist Spark Therapeutics  for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.

News for Roche Holding AG Stock (RHHBY)